Loading
Life sciences · Journal article
Frontiers in Pain Research · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Mitochondrial-derived peptides (MDPs), including humanin and MOTS-c, are endogenous peptide signaling molecules that regulate cellular stress responses and metabolic homeostasis. Mitochondrial dysfunction is a convergent downstream mechanism across diverse chronic pain states, yet existing therapies target only limited neural mechanisms. Recent preclinical evidences demonstrate that humanin and MOTS-c exert analgesic effects across multiple pain models through shared mechanisms converging on AMPK-PGC-1α-mediated mitochondrial biogenesis and suppression of oxidative stress and neuroinflammation. Humanin attenuates metabolic, toxic, and traumatic neuropathic pain while reducing pain-related markers in dorsal root ganglia. MOTS-c shows broader efficacy across neuropathic, diabetic, inflammatory, and cancer-induced bone pain models, with mechanistic evidence linking its effects to AMPK activation, microglial inhibition, and restoration of mitochondrial function. Endogenous MDP levels decline in pain states, suggesting that their loss contributes to pain pathogenesis and that restoration may be therapeutic. SHLPs, particularly SHLP2, have not been directly studied in pain but exhibit anti-inflammatory and anti-apoptotic properties that provide a plausible indirect link. This review synthesizes current evidence on MDPs in pain, and proposes priorities for translating these endogenous peptides into therapeutic strategies for chronic pain.